MediPharm Labs Corp. LABS MEDIF MLZ reported Monday its first-quarter revenue amounted to CA$5.49 million ($4.53 million), down by roughly 9% sequentially and 50% year-over-year.
Adjusted EBITDA, a non-IFRS measure, came in negative at roughly CA$6.16 million, representing an improvement from a CA$8.77 million loss in the prior quarter and a loss of CA$5.66 million in the same quarter of 2020.
Greg Hunter, CFO of the Barrie, Ontario-based company, called the quarter a "cross-over period to our future state as the preferred global cannabis API provider to medical and wellness markets."
Q1 2021 Highlights
- Gross profit was negative at CA$680 000 compared to a negative gross profit of CA$24.7 million in the previous quarter and CA$10.9 million in the same period of 2020.
- A negative gross margin was 12%, compared to a negative gross margin of 408% in the last three months of 2020 and 98% in the prior year's corresponding quarter.
- Net loss amounted to approximately CA$13.9 million, after shrinking by 55% sequentially and 37% year-over-year.
- International sales rose to CA$1.8 million over the last three months of 2020, to CA$2.1 million in the first quarter of 2021.
- The company achieved more than CA$1.5 million in cost savings.
- As of March 31, the company had CA$42.1 million in cash and cash equivalents.
"We commenced 2021 focused on establishing our presence as a pharmaceutical company while ramping up and significantly growing our international sales," Hunter added.
In October, MediPharm Labs inked a deal to supply GMP-certified medical cannabis products to German pharmaceutical giant Stada Arzneimittel AG.
Six months later, in April, the company expanded its reach in the German market by signing a two-year supply agreement with the subsidiary of the multi-country medical and recreational cannabis operator IM Cannabis IMCC IMCC, which agreed to expand its product offering in Germany in 2021.
Photo by Diyahna Lewis on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.